Background illustration for clinical trials search

Paid Clinical Trials Murfreesboro

Discover 1,239 paid clinical trials in Murfreesboro, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

for
Prostate Cancer,
Location: Nashville TN, Birmingham AL, Cincinnati OH, St Louis MO,
Sponsor: Janux Therapeutics

Sex: Male

Age: 18 - 70+

Code: NCT05519449

Phase 1, Recruiting

SNV1521 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Nashville TN, Toronto, Houston TX, Philadelphia PA,
Sponsor: Synnovation Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06220864

Phase 1, Recruiting

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

for
Non-small Cell Lung Cancer (NSCLC)
Location: Nashville TN, Houston TX
Sponsor: Pierre Fabre Medicament

Sex: All

Age: 18+

Code: NCT06567015

Phase 1, Phase 2, Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

for
Small Cell Lung Cancer
Location: Nashville TN, Chicago IL, Milwaukee WI, Buffalo NY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06780137

Phase 1, Phase 2, Recruiting

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

for
Advanced or Metastatic Breast Cancer
Location: Nashville TN
Sponsor: Kind Pharmaceuticals LLC

Sex: Female

Age: 18+

Code: NCT05187832

Phase 1, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Nashville TN, Cincinnati OH, St Louis MO, Columbus OH,
Sponsor: Fate Therapeutics

Sex: All

Age: 18+

Code: NCT06241456

Phase 1, Recruiting
New

A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

for
Lymphoma, B Cell, Lymphoma Non-Hodgkin,
Location: Nashville TN
Sponsor: Umoja Biopharma

Sex: All

Age: 18+

Code: NCT07735533

Phase 1, Phase 2, Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

for
Gaucher Disease, Cerebroside Lipidosis Syndrome,
Location: Nashville TN, Decatur GA, Greenville SC, Cincinnati OH,
Sponsor: Genzyme, a Sanofi Company

Sex: All

Age: 0+

Code: NCT00358943

Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for
Carcinoma, Non-Small Cell Lung,
Location: Nashville TN, Indianapolis IN, Springfield IL,
Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All

Age: 18+

Code: NCT04389632

Phase 1, Recruiting

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

for
Advanced HR+/HER2- Breast Cancer,
Location: Nashville TN, St Louis MO, Toronto, Houston TX,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT06726148

Phase 1, Phase 2, Recruiting

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

for
NHL, Multiple Myeloma, Blood Cancer,
Location: Nashville TN, Atlanta GA, Winston-Salem NC,
Sponsor: Indapta Therapeutics, INC.

Sex: All

Age: 18+

Code: NCT06119685

Phase 1, Phase 2, Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

for
Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
Location: Nashville TN, Atlanta GA, Cincinnati OH, St Louis MO,
Sponsor: Nuvalent Inc.

Sex: All

Age: 18+

Code: NCT06765109

Phase 3, Recruiting

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for
Neoplasms
Location: Nashville TN, Birmingham AL, Louisville KY, Atlanta GA,
Sponsor: Celgene

Sex: All

Age: 0+

Code: NCT03435796

Phase 2, Phase 3, Recruiting

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

for
Advanced Solid Tumor, Melanoma, Head and Neck Cancer,
Location: Nashville TN, St Louis MO, Chicago IL, Baltimore MD,
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT06172478

Phase 2, Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

for
Non-Small Cell Lung Cancer (NSCLC)
Location: Nashville TN, Memphis TN, Asheville NC, Dayton OH,
Sponsor: Amgen

Sex: All

Age: 18 - 70+

Code: NCT05920356

Phase 3, Recruiting

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

for
Advanced Breast Cancer
Location: Nashville TN, Atlanta GA, Germantown TN, Chicago IL,
Sponsor: Stemline Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06638307

Phase 1, Recruiting

QTX3034 in Patients With KRAS G12D Mutation

for
Solid Tumors
Location: Nashville TN, Durham NC, Fairfax VA, Tampa FL,
Sponsor: Quanta Therapeutics

Sex: All

Age: 18+

Code: NCT06227377

Phase 1, Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

for
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Location: Nashville TN, Birmingham AL, Atlanta GA, Cincinnati OH,
Sponsor: American Society of Clinical Oncology

Sex: All

Age: 12+

Code: NCT02693535

Phase 2, Recruiting

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

for
Diffuse Large B-Cell Lymphoma
Location: Nashville TN, Knoxville TN, Owensboro KY, Louisville KY,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06717347

Phase 3, Recruiting

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

for
Breast Cancer, Gastric Cancer, Esophageal Cancer,
Location: Nashville TN, Dallas TX, Houston TX, New York NY,
Sponsor: Jazz Pharmaceuticals

Sex: All

Age: 18+

Code: NCT06695845

Phase 2, Recruiting